A Postoperative Study on HVSI vs LVSI Treatment of Chronic Rhinosinusitis
Launched by UNIVERSITY OF BRITISH COLUMBIA · Dec 17, 2015
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
BACKGROUND: Chronic Rhinosinusitis (CRS) is a common inflammatory condition of the upper respiratory tract lasting more than 8 to 12 weeks. Major symptoms include facial congestion/fullness, facial pain/pressure, nasal obstruction/blockage, purulent nasal drainage, and reduction or loss of smell. The diagnosis must include two major symptoms and either endoscopic evidence of polyps, edema or mucopurulent discharge from the middle meatus and/or CT changes in the mucosa of sinuses or osteomeatal complexes.
CRS has an estimated prevalence of 5% in the Canadian population, and up to 16% in som...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented diagnosis of unilateral or bilateral CRS
- • Documented failed medical treatment of CRS
- • 18 to 65 years of age
- • Planned ESS for the treatment of CRS
- • Able to read and understand English
- Exclusion Criteria:
- • Pregnant
- • Cystic Fibrosis
- • Diagnosed immotile cilia syndrome
- • Diagnosed immunodeficiency syndrome
- • Diagnosed fungal sinusitis
- • Sinonasal tumours or obstructive lesions
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Arif Janjua, MD
Principal Investigator
Vancouver Coastal Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials